Home › Trials › Stomach & bowel

Rectal cancer

A Study of Amivantamab and FOLFIRI Versus Cetuximab/Bevacizumab and FOLFIRI in Participants With KRAS/NRAS and BRAF Wild-type Colorectal Cancer Who Have Previously Received Chemotherapy

Who can joinAdults

Age18+ years

Kind of studyPhase 3: compared with usual treatment

What it testsA medicine

The full list of who can and cannot join is on the registry. Ask the trial team, or write to us and we will explain it in simple words.

Where to go

8 hospitals in India taking patients for this trial.

Rajiv Gandhi Cancer Institute and Research CentreDelhiDirections ↗

Asian Institute Of GastroenterologyHyderabadDirections ↗

B P Poddar Hospital and Medical research LimitedKolkataDirections ↗

Tata Memorial HospitalMumbaiDirections ↗

Safdarjung HospitalNew DelhiDirections ↗

Deenanath Mangeshkar Hospital and Research CentrePuneDirections ↗

Mahamana Pandit Madan Mohan Malviya Cancer CentreVaranasiDirections ↗

Christian medicalVelloreDirections ↗

Registry summary (technical)

The purpose of this study is to compare how long the participants are disease-free (progression-free survival) and and the length of time until a participant dies (overall survival), when treated with amivantamab and chemotherapy with 5-fluorouracil, leucovorin calcium (folinic acid) or levoleucovorin, and irinotecan hydrochloride (FOLFIRI) versus either cetuximab or bevacizumab and FOLFIRI given to participants with Kirsten rat sarcoma viral oncogene/ neuroblastoma RAS viral oncogene homolog (KRAS/ NRAS) and v-raf murine sarcoma viral oncogene homolog B (BRAF) wild-type recurrent, unresectabl…

Sponsor: Janssen Research & Development, LLC
NCT06750094 on ClinicalTrials.gov
Last updated on the registry 25 Sep 2026 · read by us 20 Oct 2026

Rectal cancer

Where to go

Need help reaching the trial team? Write to us.